Evidence map›Paper›PMID 42245771›Full record

ArticleJAC-antimicrobial resistance2026

Katsunori Yanagihara, Kazuhiro Tateda, Yohei Doi, Satoshi Takahashi, Hiroki Ohge, Koju Itahashi, Hayato Okade, Hiroshige Mikamo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kazuhiro TatedaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Yohei DoiDepartments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan.
Satoshi TakahashiDepartment of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hiroki OhgeDepartment of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.
Koju ItahashiR&D Division, Meiji Seika Pharma Co., Ltd, Tokyo, Japan.
Hayato OkadeR&D Division, Meiji Seika Pharma Co., Ltd, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2570-6056
Hiroshige MikamoDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Nacubactam is a novel diazabicyclooctane carbapenemase inhibitor that, in combination with cefepime or aztreonam, has been submitted for regulatory approval in Japan for treating serious Gram-negative infections. This study aimed to evaluate the Methods: Minimum inhibitory concentration (MIC) values of 376 CRE isolates from 6 medical institutions in Japan were determined according to the Clinical and Laboratory Standards Institute (CLSI) methods. Results were interpreted using clinical breakpoints of the CLSI document M100 (2025) and the European Committee on Antimicrobial Susceptibility Testing clinical breakpoints, version 15.0 (2025). Results: The predominant CRE isolates were Conclusions: Cefepime-nacubactam and aztreonam-nacubactam have excellent antibacterial activities against CPE and non-CP-CRE, supporting their potential as therapeutic options for CRE infections.

Identifiers

PMID42245771
PMCPMC13231151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.